Switching from intravenous to subcutaneous vedolizumab maintenance treatment; feasibility, safety and clinical outcome

被引：0
|
作者：
Wiken, T. [1 ,2 ]
Hoivik, M. L. [1 ,2 ]
Buer, L. [1 ]
Bolstad, N. [3 ]
Moum, B. A. [1 ,2 ]
Medhus, A. W. [1 ]
机构：
[1] Oslo Univ Hosp, Dept Gastroenterol, Oslo, Norway
[2] Univ Oslo, Inst Clin Med, Oslo, Norway
[3] Oslo Univ Hosp, Dept Med Biochem, Oslo, Norway
来源：
JOURNAL OF CROHNS & COLITIS | 2022年 / 16卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P376
引用
收藏
页码：I378 / I379
页数：2
相关论文
共 50 条
  • [1] Switching from intravenous to subcutaneous vedolizumab maintenance treatment; feasibility, safety and clinical outcome
    Wiken, T.
    Hoivik, M. L.
    Buer, L.
    Bolstad, N.
    Moum, B. A.
    Medhus, A. W.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I378 - I379
  • [2] SWITCHING INTRAVENOUS VEDOLIZUMAB MAINTENANCE TREATMENT TO SUBCUTANEOUS VEDOLIZUMAB TREATMENT FOR INFLAMMATORY BOWEL DISEASE
    Volkers, Adriaan
    Straatmijer, Tessa
    Duijvestein, Marjolijn
    Sales, Amber
    Levran, Amit
    Van Schaik, Fiona
    Maljaars, Jeroen
    Gecse, Krisztina B.
    Ponsioen, Cyriel Y.
    Grootjans, Joep
    Hanzel, Jurij
    Tack, Greetje
    Jansen, Jeroen M.
    Hoentjen, Frank
    De Boer, Nanne
    van der Marel, Sander
    Dijkstra, Gerard
    Oldenburg, Bas
    Lowenberg, Mark
    Meulen-De Jong, Andrea V.
    D'Haens, Geert
    GASTROENTEROLOGY, 2022, 162 (07) : S820 - S821
  • [3] Real World Effectiveness, Safety and Pharmacokinetics of Switching Intravenous Vedolizumab Maintenance treatment to Subcutaneous Vedolizumab Therapy for Inflammatory Bowel Disease
    Volkers, A.
    Straatmijer, T.
    Duijvestein, M.
    Sales, A.
    Levran, A.
    van Schaik, F.
    Jeroen, M.
    Gecse, K.
    Ponsioen, C.
    Grootjans, J.
    Hanzel, J.
    Tack, G.
    Jansen, J.
    Hoentjen, F.
    de Boer, N.
    van der Marel, S.
    Dijkstra, G.
    Oldenburg, B.
    Lowenberg, M.
    van der Meulen, A.
    D'Haens, G.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I108 - I109
  • [4] Real-world experience of switching from intravenous to subcutaneous vedolizumab maintenance treatment for inflammatory bowel diseases
    Volkers, Adriaan
    Straatmijer, Tessa
    Duijvestein, Marjolijn
    Sales, Amber
    Levran, Amit
    van Schaik, Fiona
    Maljaars, Jeroen
    Gecse, Krisztina
    Ponsioen, Cyriel
    Grootjans, Joep
    Hanzel, Jurij
    Tack, Greetje
    Jansen, Jeroen
    Hoentjen, Frank
    de Boer, Nanne
    van der Marel, Sander
    Dijkstra, Gerard
    Oldenburg, Bas
    Lowenberg, Mark
    van der Meulen, Andrea
    D'Haens, Geert
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2022, 56 (06) : 1044 - 1054
  • [5] Letter: Experience of switching vedolizumab treatment from intravenous to subcutaneous formulation in Hungary
    Bacsur, Peter
    Ilias, Akos
    Resal, Tamas
    Kata, Diana
    Molnar, Tamas
    Farkas, Klaudia
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2023, 58 (02) : 262 - 263
  • [6] Effectiveness and Safety of Switching from Intravenous to Subcutaneous Vedolizumab Formulation in Inflammatory Bowel Disease Patients in Clinical Remission
    Parisio, Laura
    Settanni, Carlo Romano
    Varca, Simone
    Laterza, Lucrezia
    Lopetuso, Loris Riccardo
    Napolitano, Daniele
    Schiavoni, Elisa
    Turchini, Laura
    Fanali, Caterina
    Alfieri, Norma
    Pizzoferrato, Marco
    Papa, Alfredo
    Pafundi, Pia Clara
    Armuzzi, Alessandro
    Gasbarrini, Antonio
    Pugliese, Daniela
    Scaldaferri, Franco
    JOURNAL OF GASTROINTESTINAL AND LIVER DISEASES, 2023, 32 (04) : 452 - 459
  • [7] Switching from intravenous to subcutaneous vedolizumab maintenance treatment in patients with inflammatory bowel disease followed by therapeutic drug monitoring
    Wiken, Thea H.
    Hoivik, Marte L.
    Buer, Lydia
    Warren, David J.
    Bolstad, Nils
    Moum, Bjorn A.
    Anisdahl, Karoline
    Smastuen, Milada C.
    Medhus, Asle W.
    SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2023, : 863 - 873
  • [8] Take vedolizumab home: transition from intravenous to subcutaneous treatment
    Huang, Kaituo
    Yao, Lingya
    Liu, Jing
    Cao, Qian
    THERAPEUTIC ADVANCES IN CHRONIC DISEASE, 2024, 15
  • [9] Real-life experiences of switching from intravenous to subcutaneous vedolizumab maintenance therapy in patients with inflammatory bowel disease
    Kolehmainen, Sara
    Rautakorpi, Jaakko
    Loyttyniemi, Eliisa
    Af Bjorkesten, Clas-Goeran
    Arkkila, Perttu
    Salminen, Kimmo
    Sipponen, Taina
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2024, 36 (10) : 1193 - 1201
  • [10] Clinical and biomarker remission is maintained after switch from monthly dosed intravenous to subcutaneous maintenance treatment with vedolizumab in Inflammatory Bowel Disease
    Pintar, S.
    Hanzel, J.
    Smrekar, N.
    Kozelj, M.
    Drobne, D.
    Kurent, T.
    Stabuc, B.
    Novak, G.
    JOURNAL OF CROHNS & COLITIS, 2023, 17 : 834 - 834
12345